PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS BEVACIZUMAB VERSUS CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
The goal of this clinical research study is to find out if adding bevacizumab to the combination of temozolomide and radiation will help to control glioblastoma better than treatment with temozolomide and radiation alone. Researchers will study if the genetic pattern in the tumor cells is related to each participant's response to the bevacizumab and the overall outcome. The safety of these 2 combination treatments will also be studied.
Disease Group: Advanced Cancers,Brain,CNS
Treatment Agent: Bevacizumab,Irinotecan,Temozolomide
Treatment Location: Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimatated Length of Stay in Houston: N/A
Sponsor: NCI/RTOG,Rider for the Cure
Return Visit: Every 2 weeks
Home Care: Patients will take temozolomide at home.
1. Primary To determine whether the addition of bevacizumab to temozolomide(TMZ) and radiation improves efficacy as measured by progression-free and/or overall survival. 2. Secondary 2.1 To determine whether the tumor molecular profile conferring a mesenchymal/angiogenic phenotype is associated with a selective increase in benefit, as measured by either overall survival or progression-free survival, from the addition of bevacizumab. 2.2 To compare and record the toxicities of the conventional and bevacizumab-containing regimens. 3. Tertiary 3.1 The primary focus is to determine the differential acute effects associated with the addition of bevacizumab to temozolomide and radiation, as compared to the conventional arm, on measures of neurocognitive function, health-related quality of life, and symptoms during radiation and across the longitudinal progression-free interval. 3.2 To determine the relationship of neurocognitive function, health-related quality of life, and symptoms, with progression-free and overall survival. 3.3 To determine the association between tumor molecular profile (i.e., mesenchymal/angiogenic phenotype and proneural phenotype) and neurocognitive function, health-related quality of life, and symptoms. 3.4 To describe the association between health-related quality of life as measured by the EORTC Quality of Life Questionnaire-Core 30/Brain Cancer Module-20 (EORTC-QL30/BCM20) and mean symptom severity as measured by the M. D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) in patients enrolled in this study. 3.5 To evaluate the relationship between self-reported neurocognitive function(NCF) and objectively measured tests of NCF. 4 American College of Radiology Imaging Network (ACRIN) 6686 Imaging Objectives 4.1 Primary Imaging Objectives 4.1.1 To assess the association between overall survival and Ktrans change from T1 to T2. 4.1.2 To assess the association between overall survival and spin echo cerebral blood volume (CBV) change from T1 to T2. 4.2 Secondary Imaging Objectives 4.2.1 To assess the association between progression-free survival and Ktrans change from T1 to T 4.2.2 To assess the association between progression-free survival and spin echo CBV change from T1 to T2. 4.2.3 To assess the association between values of Ktrans and spin echo CBV measured separately at T0 and at T1, and overall and progression-free survival. 4.2.4 To assess the association between overall survival and Ktrans changes from T0 to T1 and from T2 to T3. 4.2.5 To assess the association between overall survival and spin echo CBV changes from T0 to T1 and from T2 to T3. 4.2.6 To assess the association between overall survival and apparent diffusion coefficient (ADC) change from T0 to T1. 4.2.7 To assess the association between overall survival and ADC change from T1 to T2. 4.2.8 To assess the association between progression-free survival and ADC change from T0 to T1.
IRB Review and Approval Date: 07/08/2009
Recruitment Status: Not Accepting
Projected Accrual: 942
1) Histologically proven diagnosis of glioblastoma or gliosarcoma (WHO
grade IV) confirmed by central review prior to step 2 registration
2) Tumor tissue that is determined by central pathology review prior to step 2 registration to be of sufficient size for analysis of MGMT status and determination of molecular profile. a) Patients must have at least 1 block of tumor tissue; submission of 2 blocks is strongly encouraged to maximize the chances of eligibility. At least 1 cm^3 of tissue composed primarily of tumor must be present. b) CUSA (Cavitron ultrasonic aspirator)-derived material is not allowed; fresh frozen tumor tissue acquisition is encouraged. c) Diagnosis must be made by surgical excision, either partial or complete;
3) ( 2. continued) stereotactic biopsy is not allowed because it will not provide sufficient tissue for MGMT analysis. d) The tumor tissue should be sent as soon as possible to maximize the likelihood of eligibility. Tumor tissue should be submitted by 4 weeks after the surgical procedure so that study registration and treatment can commence by the mandatory 5 week post-surgery outer limit. e) sites must submit tissue directly to Dr. Aldape in order to obtain the MGMT analysis. Patients from sites not following the protocol-specified process for obtaining MGMT results will be made ineligible.
4) The tumor must have a supratentorial component.
5) History/physical examination within 14 days prior to registration.
6) The patient must have recovered from the effects of surgery, postoperative infection, and other complications before study registration.
7) A diagnostic contrast-enhanced Magnetic Resonance Imaging (MRI) of the brain must be performed preoperatively and postoperatively prior to the initiation of radiotherapy. The postoperative scan must be performed within 28 days prior to study registration.
8) (7. continued) a) An MRI or Computed Tomography (CT) scan (potentially in addition to the postoperative scan) must be obtained within 1 week prior to registration and must not demonstrate significant postoperative hemorrhage defined as > 1 cm diameter of blood. If > 1 cm of acute blood is detected, the patient will be ineligible for this trial. The radiation planning MRI or CT scan may be used to determine presence of hemorrhage.
9) (8 contined) b) Patients unable to undergo MR imaging because of non-compatible devices can be enrolled, provided pre- and postoperative contrast-enhanced CT scans are obtained and are of sufficient quality. Preoperative and postoperative scans must be the same type. Such patients cannot be enrolled into the advanced imaging component.
10) Documentation of steroid doses within 14 days prior to registration.
11) Karnofsky performance status >/= 70.
12) Age >/= 18
13) CBC/differential obtained within 14 days prior to registration on study, with adequate bone marrow function defined as follows: a) Absolute neutrophil count (ANC) >/= 1,800 cells/mm^3; b) Platelets >/= 100,000 cells/mm^3; c) Hemoglobin >/= 10.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb >/= 10.0 g/dl is acceptable.)
14) Adequate renal function, as defined below: a) BUN </= 30 mg/dl within 14 days prior to study registration. b) Creatinine </= 1.7 mg/dl within 14 days prior to study registration. c) Urine protein screened by urine analysis for urine protein creatinine (UPC) ratio. For UPC ratio > 0.5, 24-hour urine protein should be obtained and the level should be < 1000 mg.
15) Adequate hepatic function, as defined below: a) Bilirubin </= 2.0 mg/dl within 14 days prior to study registration b) ALT/AST </= 3 x normal range within 14 days prior to study registration
16) Systolic blood pressure </= 140 mg Hg or diastolic pressure </= 90 mg Hg within 14 days prior to study registration. Electrocardiogram without evidence of acute cardiac ischemia within 14 days prior study registration
17) Prothrombin time/international normalized ratio (PT INR) < 1.4 for patients not on warfarin confirmed by testing within 14 days prior to study registration. Patients on full-dose anticoagulants (e.g., warfarin or LMW heparin) must meet both of the following criteria: a) No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices). b) In-range INR (between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin.
18) Patient must provide study specific informed consent prior to study entry.
19) Women of childbearing potential and male participants must practice adequate contraception.
20) For females of child-bearing potential, negative serum pregnancy test within 14 days prior to registration
1) Prior invasive malignancy (except for non-melanomatous skin cancer)
unless disease free for >/= 3 years. (For example, carcinoma in situ
of the breast, oral cavity, and cervix are all permissible).
2) Recurrent or multifocal malignant gliomas
3) Metastases detected below the tentorium or beyond the cranial vault.
4) Prior chemotherapy or radiosensitizers for cancers of the head and neck region; note that prior chemotherapy for a different cancer is allowable, except prior temozolomide or bevacizumab. Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permitted.
5) Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields.
6) Severe, active co-morbidity as follows: a) Unstable angina and/or congestive heart failure within the last 6 months. b) Transmural myocardial infarction within the last 6 months. c) Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of >/= 2 mm using the analysis of an EKG performed within 14 days of registration . d) New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to registration. e) History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within 6 months
7) ( 6. continued) f) Serious and inadequately controlled cardiac arrhythmia. g) Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease. h) Evidence of bleeding diathesis or coagulopathy. i) Serious or non-healing wound, ulcer, or bone fracture or history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration, with the exception of the craniotomy for tumor resection.
8) (7. continued) j) Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration. k) Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration. l) Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol.
9) (8. continued) m) Acquired immune deficiency syndrome (AIDS) based upon current Center of Disease Control (CDC) definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. n) Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity.
10) (9. continued) o) Any other major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy.
11) Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
12) Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant due to study drug.
13) Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study.
14) For ACRIN 6686 Advanced Imaging: Inability to undergo MRI (e.g., due to safety reasons, such as presence of a pacemaker).